301331.SHE Enwei Pharmaceutical Co. Ltd. A
- Market cap
- CNY 2.43B
- P/E
- 59.0x
- P/B
- 2.11x
- ROE
- 2.9%
- Dividend yield
- 0.86%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301331.SHE undervalued?
Graham number301331.SHE trades 135.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Enwei Pharmaceutical Co. Ltd. A fundamental analysis
No fundamental analysis for Enwei Pharmaceutical Co. Ltd. A yet.
Enwei Pharmaceutical Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Enwei Pharmaceutical Co. Ltd. A
Enwei Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of Chinese medicines and chemical drugs in China. The company offers drugs in the areas of gynecology, pediatrics, respiratory, stomatology, digestive, cardiovascular, hepatobiliary, and dermatology under the Jieeryin, Haowayou, and Likeshu brands. It also provides products for cold and fever relief, dental care, warming/nourishing/tonic purposes, and ot…
Full company profileEnwei Pharmaceutical Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Enwei Pharmaceutical Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 621M | 634M | 680M | 692M | 785M | 812M | 901M | 754M |
| Gross Profit | 406M | 364M | 383M | 347M | 402M | 413M | 446M | 375M |
| Operating Income | 116M | 126M | 120M | 81.6M | 92.2M | 50.6M | 61.1M | 29.9M |
| EBITDA | 267M | 238M | 184M | 113M | 136M | 95.8M | 115M | 38.8M |
| Net Income | 82.6M | 98.7M | 102M | 67.8M | 86.3M | 37.5M | 51.9M | 29.9M |
| EPS | 1.57 | 1.27 | 1.31 | 0.65 | 0.83 | 0.36 | 0.50 | 0.29 |
| Balance Sheet | ||||||||
| Total Assets | 748M | 849M | 869M | 1.41B | 1.34B | 1.50B | 1.55B | 1.44B |
| Total Liabilities | 264M | 262M | 227M | 253M | 234M | 447M | 478M | 408M |
| Shareholders' Equity | 405M | 587M | 642M | 1.15B | 1.10B | 1.06B | 1.07B | 1.03B |
| Cash & Short-term Investments | 47.4M | 63.0M | 64.3M | 342M | 236M | 370M | 362M | 338M |
| Cash Flow | ||||||||
| Operating Cash Flow | 120M | 78.5M | 87.6M | 62.4M | 84.0M | 78.9M | 110M | - |
| Capital Expenditure | 21.2M | 31.2M | 38.2M | 23.6M | 134M | 50.2M | 56.4M | 55.9M |
| Free Cash Flow | 98.5M | 47.4M | 49.4M | 38.8M | -50.0M | 28.7M | 53.2M | 58.5M |
| Ratios | ||||||||
| ROE | 20.4% | 16.8% | 15.8% | 5.9% | 7.8% | 3.5% | 4.8% | 2.9% |
| ROA | 11.0% | 11.6% | 11.7% | 4.8% | 6.5% | 2.5% | 3.3% | 2.1% |
| Net Profit Margin | 13.3% | 15.6% | 15.0% | 9.8% | 11.0% | 4.6% | 5.8% | 4.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Enwei Pharmaceutical Co. Ltd. A dividends
- Dividend yield
- 0.86%
- Forward dividend
- 1.03 CNY
- Payout ratio
- 40.0%
- Ex-dividend date
- May 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 20.8M | 0.20 | 40.0% |
| 2024 | CNY 57.0M | 0.55 | 151.9% |
| 2023 | CNY 112M | 1.08 | 130.0% |
| 2022 | - | - | - |
| 2021 | CNY 46.0M | 0.59 | 45.2% |
| 2020 | CNY 1.58M | 0.02 | 1.6% |
| 2019 | CNY 81.3M | 1.55 | 98.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.48:1 on May 23, 2024.
Who owns Enwei Pharmaceutical Co. Ltd. A
- Insiders 66.61%
- Institutions 3.19%
- Public & others 30.20%
- Shares outstanding 103M
- Free float 32.8M
Enwei Pharmaceutical Co. Ltd. A company profile
- Company name
- Enwei Pharmaceutical Co. Ltd. A
- Ticker
- 301331.SHE
- ISIN
- CNE100005LC7
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,501
- Fiscal year end
- December
- Address
- No. 458, Shuanghua Road, Chengdu, China, 610200
- Phone
- 86 28 8154 8888
- Website
- enwei.com.cn
About Enwei Pharmaceutical Co. Ltd. A
Enwei Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of Chinese medicines and chemical drugs in China. The company offers drugs in the areas of gynecology, pediatrics, respiratory, stomatology, digestive, cardiovascular, hepatobiliary, and dermatology under the Jieeryin, Haowayou, and Likeshu brands. It also provides products for cold and fever relief, dental care, warming/nourishing/tonic purposes, and other uses; ointments, suppositories, capsules, effervescent tablets, and antibacterial washes; hygiene products, disinfectants, medical devices, pharmaceutical packaging materials and containers, and daily chemical products; compound preparations, oral liquids and solutions, syrups, and decoctions; and tablets, granules, powders, large honey and water pills, water-honey and concentrated pills, wax pills, and syrups. In addition, the company engages in medical research and experimental development. Enwei Pharmaceutical Co., Ltd. was founded in 1986 and is based in Chengdu, China.
Enwei Pharmaceutical Co. Ltd. A management
6- Mr. Yongjiang XueChairman & CEO · born 1971
- Mr. Xue GangVice Chairman & President · born 1973
- Mr. Dawei HuCFO, VP & Secretary of the Board · born 1987
- Mr. Zhuang YanVP & Director · born 1961
- Mr. Lei ChenVice President · born 1976
- Hui NingAccounting Supervisor